Aggressive Cholesterol Lowering May Prevent First Heart Attacks in Patients With Diabetes

In a landmark finding that could redefine preventative heart care, new data from the VESALIUS-CV trial suggest that intensive cholesterol treatment should begin far earlier than current medical standards dictate. The findings, presented at the American College of Cardiology 2026 Scientific Session, reveal that the drug evolocumab (Repatha; Amgen) significantly slashes the risk of major cardiac events in high-risk patients who have diabetes but no known history of heart disease or significant arterial clogging.^1,2

For decades, the medical community has operated under a reactive model for the most potent cholesterol-lowering drugs, largely reserving them for secondary prevention—patients who have already survived a heart attack or stroke.² However, this new subgroup analysis of 3655 patients challenges that status quo, suggesting a 31% reduction in major adverse cardiovascular events (MACE) among those treated with evolocumab compared to a placebo.¹

“I think this study changes the paradigm,” stated Nicholas Marston, MD, lead author and cardiologist at Brigham and Women’s Hospital. “It’s a message to physicians and patients that we don’t have to wait until someone has atherosclerosis to treat them intensively. We can—and should—be much more proactive.”³

The Science of Prevention

Evolocumab is a PCSK9 inhibitor, a monoclonal antibody that helps the liver more effectively clear low-density lipoprotein cholesterol (LDL-C) from the blood. While statins remain the frontline defense, they are not always enough for high-risk individuals.

In the VESALIUS-CV trial, participants—who had a median age of 65—were already receiving optimized statin therapy. Despite this, those who added evolocumab saw their LDL-C levels decrease from a median of 111 mg/dL to a staggering 44 mg/dL after 96 weeks. This level of reduction is typically only targeted for the highest-risk patients who have already experienced multiple cardiovascular disasters.^1,2

The clinical results were equally stark. The study measured 2 primary composite end points: 3-P MACE, which was a composite of heart disease death, heart attack, or ischemic stroke that saw a reduced risk of 31%; and 4-P MACE, which encompassed the same 3 events plus the need for revascularization, which also saw a reduced risk of 31%.^1,2

Breaking the "Wait and See" Cycle

Under current American Heart Association and American College of Cardiology guidelines, patients with diabetes but without known heart disease are usually prescribed moderate-intensity statins. More aggressive treatments are often only considered if cholesterol remains high.^1,2

The VESALIUS-CV data suggest that this wait and see approach may be missing a critical window. The study found that while the benefits of the drug were evident by the 1-year mark, the gap between the treated group and the placebo group actually widened to 40% after the first year. This suggests that the longer a patient is on the intensive therapy, the more protection they build against future events.

"Over the decades, we’ve moved to lower and lower LDL-C goals... and we’ve continued to see benefit," Marston noted. "Now, we’re in this process of moving earlier and earlier in the disease course."³

Safety and Considerations

Crucially, the study reported that the drug was well-tolerated. Serious adverse events leading to the discontinuation of the drug were nearly identical between the evolocumab (4.1%) and placebo (4.3%) groups.^1,2

However, the researchers acknowledged certain limitations. The study population was predominantly White (93%) and specifically focused on those with diabetes. Additionally, because coronary imaging was not required for all participants, it is possible some patients had undiagnosed "silent" plaque buildup. Nevertheless, the authors argue this reflects real-world clinical practice, where routine imaging for primary prevention is not standard.^1,2

A New Standard for High-Risk Patients?

The implications are significant. The findings suggest that for patients with diabetes at high cardiovascular risk, the target LDL-C should perhaps be the same ultra-low goal currently reserved for heart attack survivors.¹

As the medical community reviews these findings, the message from the VESALIUS-CV investigators is clear: intensive lipid-lowering therapy should not be viewed as a last resort for survivors, but as a preventative shield for those at risk. By intervening earlier in the disease process, clinicians may finally be able to stop the first heart attack before it ever happens.

REFERENCES

1. Marston N. Evolocumab in patients without significant atherosclerosis: results from VESALIUS-CV. Preesented at: American College of Cardiology 2026 Scientific Sessions. March 28, 2026; New Orleans, LA.

2. Marston NA, Bohula EA, Bhatia AK, et al. Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes. JAMA. 2026. doi:10.1001/jama.2026.3277.

3. Evolocumab cuts cardiac risk in patients without known atherosclerosis and with diabetes. News release. American College of Cardiology. March 28, 2026. Accessed March 28, 2026. https://www.acc.org/Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-345pm-vesaliuscv-acc-2026